SGMT Sagimet Biosciences Inc

102

$4.04

$0.06

(1.51%)

Today

Market Cap	$86.36M
Volume (M)	59,426.00
52-Wk High	$18.33
52-Wk Low	$2.13

ST Data

Watchers

New Watcher Rank

Fundamentals

Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst ClinicGlobe Newswire • 4 days ago

SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Share to Feed

Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development SummitGlobe Newswire • 10 days ago

SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare ConferenceGlobe Newswire • 16 days ago

SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Promising Lipidomic Data and Financial Stability Bolsters Buy Recommendation for Sagimet BiosciencesTipRanks Financial Blog • 25 days ago

Analyst Jonathan Wolleben of JMP Securities reiterated a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT Research Report), with a price tar...

Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate UpdatesGlobe Newswire • 25 days ago

On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-breaker, accepted at the American...

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting 2023Globe Newswire • 28 days ago

Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...

Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting 2023Globe Newswire • about 2 months ago

SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...

Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor ConferenceGlobe Newswire • about 2 months ago

SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that...

Sagimet Biosciences management to meet virtually with Piper SandlerThe Fly • about 2 months ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent GlioblastomaGlobe Newswire • 2 months ago

SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...